Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.74B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$760M |
| 3 |
Alibaba
BABA
|
+$429M |
| 4 |
Stellantis
STLA
|
+$372M |
| 5 |
CERN
Cerner Corp
CERN
|
+$304M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.85B |
| 2 |
Microsoft
MSFT
|
+$1.75B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.22B |
| 4 |
Amazon
AMZN
|
+$1.04B |
| 5 |
iShares US Real Estate ETF
IYR
|
+$924M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.06% |
| 2 | Financials | 14.44% |
| 3 | Healthcare | 10.25% |
| 4 | Consumer Discretionary | 9.7% |
| 5 | Communication Services | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Palomar
PLMR
$3.61B
| $1.32M | ﹤0.01% |
20,639
-11,412
| -36% | -$648K |
|
2127
Aura Biosciences
AURA
$740M
| $1.31M | ﹤0.01% |
+59,697
| New | +$1.14M |
|
|
NVEE
2128
DELISTED
NV5 Global
NVEE
| $1.31M | ﹤0.01% |
39,444
-28,972
| -42% | -$852K |
|
2129
Navient
NAVI
$880M
| $1.31M | ﹤0.01% |
76,965
-160,469
| -68% | -$2.95M |
|
2130
Cohen & Steers
CNS
$4.32B
| $1.31M | ﹤0.01% |
15,218
-25,159
| -62% | -$2.08M |
|
2131
Harmonic Inc
HLIT
$1.34B
| $1.31M | ﹤0.01% |
140,759
-52,491
| -27% | -$514K |
|
|
SUM
2132
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $1.31M | ﹤0.01% |
42,766
-132,275
| -76% | -$4.41M |
|
|
TGI
2133
DELISTED
Triumph Group
TGI
| $1.3M | ﹤0.01% |
51,615
-31,665
| -38% | -$703K |
|
|
DHR.PRB
2134
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| $1.3M | ﹤0.01% |
+826
| New | +$1.26M |
|
2135
Community Health Systems
CYH
$417M
| $1.29M | ﹤0.01% |
108,880
-58,004
| -35% | -$705K |
|
|
ICPT
2136
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.29M | ﹤0.01% |
79,384
+37,305
| +89% | +$584K |
|
|
ZWRK
2137
DELISTED
Z-Work Acquisition Corp. Class A Common Stock
ZWRK
| $1.29M | ﹤0.01% |
+132,000
| New | +$1.29M |
|
2138
NeoGenomics
NEO
$2.09B
| $1.29M | ﹤0.01% |
106,212
-50,288
| -32% | -$1.06M |
|
2139
Syndax Pharmaceuticals
SNDX
$1.69B
| $1.29M | ﹤0.01% |
74,234
-701,242
| -90% | -$11.8M |
|
2140
PUT
Grab
GRAB
$15.2B
| $1.29M | ﹤0.01% |
+368,000
| New | +$1.86M |
|
|
VGR
2141
DELISTED
Vector Group Ltd.
VGR
| $1.29M | ﹤0.01% |
106,787
-79,650
| -43% | -$886K |
|
2142
Concentrix
CNXC
$1.56B
| $1.28M | ﹤0.01% |
+7,671
| New | +$1.46M |
|
|
DVAX
2143
DELISTED
Dynavax Technologies
DVAX
| $1.27M | ﹤0.01% |
117,553
-18,841
| -14% | -$229K |
|
|
BLUA
2144
DELISTED
BlueRiver Acquisition Corp.
BLUA
| $1.27M | ﹤0.01% |
+130,002
| New | +$1.27M |
|
|
AZEK
2145
DELISTED
The AZEK Co
AZEK
| $1.27M | ﹤0.01% |
+51,245
| New | +$1.61M |
|
2146
Tompkins Financial
TMP
$1.46B
| $1.27M | ﹤0.01% |
16,245
-8,113
| -33% | -$654K |
|
2147
Hertz
HTZ
$477M
| $1.27M | ﹤0.01% |
+57,308
| New | +$1.2M |
|
2148
Xencor
XNCR
$1.48B
| $1.27M | ﹤0.01% |
47,522
-26,484
| -36% | -$854K |
|
2149
CACI
CACI
$11.6B
| $1.26M | ﹤0.01% |
4,188
-1,459
| -26% | -$403K |
|
2150
Travere Therapeutics
TVTX
$5.21B
| $1.26M | ﹤0.01% |
+48,901
| New | +$1.3M |
|
Similar funds
Barclays's Q1 2022 Portfolio in Review
As of Q1 2022, Barclays held 5,876 positions worth $128B, down 52% from $268B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Barclays withdrew a net $131B in Q1 2022, closing 907 positions and reducing 2,310 holdings. Its most notable exit was Nuance Communications, Inc., an estimated $631M position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Barclays opened a new position in Stellantis worth $331M.
- Barclays's largest Q1 2022 buy was Stellantis: 20,333,315 shares worth $331M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2022, an estimated $1.74B increase.
- Barclays's biggest Q1 2022 reduction was Apple, cutting an estimated $1.85B.
- Barclays fully exited Nuance Communications, Inc. in Q1 2022, selling an estimated $631M.
- Barclays's ten largest holdings make up 22% of its $128B portfolio in Q1 2022.
- Barclays opened 1,592 new positions and closed 907 in Q1 2022.
- Barclays's portfolio value fell 52% quarter-over-quarter to $128B.
Based on Barclays's 13F filing for Q1 2022, filed 16 May 2022.